MY104316A - Deravatives substituted at methylamino nitrogen - Google Patents

Deravatives substituted at methylamino nitrogen

Info

Publication number
MY104316A
MY104316A MYPI88000629A MYPI19880629A MY104316A MY 104316 A MY104316 A MY 104316A MY PI88000629 A MYPI88000629 A MY PI88000629A MY PI19880629 A MYPI19880629 A MY PI19880629A MY 104316 A MY104316 A MY 104316A
Authority
MY
Malaysia
Prior art keywords
formula
substituted
deravatives
methylamino
nitrogen
Prior art date
Application number
MYPI88000629A
Inventor
Giorgio Caravatti Dr
Andreas Fredenhagen Dr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY104316A publication Critical patent/MY104316A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

N- SUBSTITUTED DERIVATIVES OF STAUROSPORINE OF THE GENERAL FORMULA @@(FORMULA 1)@@IN WHICH [STAU] REPRESENTS A RESIDUE OF THE PARTIAL FORMULA@@(FORMULA 2)[STAU]@@AND R REPRESENTS A HYDROCARBYL RADICAL R0 OR AN ACYL RADICAL AC, WHICH RADICALS PREFERABLY HAVE A MAXIMUM OF 30 CARBON ATOMS, AND SALTS OF COMPOUNDS OF THE FORMULA I HAVING SALT- FORMING PROPERTIES, ARE DISTINGUISHED AS SELECTIVE INHIBITORS OF PROTEINKINASE C. THEY ARE MANUFACTURED BY CONVENTIONAL ALKYLATION OR ACYLATION, RESPECTIVELY, OF STAUROSPORINE.
MYPI88000629A 1987-06-15 1988-06-09 Deravatives substituted at methylamino nitrogen MY104316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH224487 1987-06-15
CH144088 1988-04-19

Publications (1)

Publication Number Publication Date
MY104316A true MY104316A (en) 1994-03-31

Family

ID=25687663

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88000629A MY104316A (en) 1987-06-15 1988-06-09 Deravatives substituted at methylamino nitrogen

Country Status (20)

Country Link
EP (1) EP0296110B1 (en)
JP (1) JP2708047B2 (en)
KR (1) KR970001529B1 (en)
AT (1) ATE134375T1 (en)
AU (1) AU617324B2 (en)
CA (1) CA1337763C (en)
DE (1) DE3855015D1 (en)
DK (1) DK175507B1 (en)
ES (1) ES2083956T3 (en)
FI (1) FI89362C (en)
GR (1) GR3019064T3 (en)
HK (1) HK1003788A1 (en)
HU (1) HU201329B (en)
IE (1) IE70523B1 (en)
IL (1) IL86632A0 (en)
MY (1) MY104316A (en)
NO (1) NO170634C (en)
NZ (1) NZ225018A (en)
PT (1) PT87719B (en)
YU (1) YU115488A (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (en) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd Ucn-01 and production thereof
WO1989007105A1 (en) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
CZ280738B6 (en) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituted pyrroles, their use for preparing medicaments and medicaments based thereon
USRE36736E (en) * 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
DE3924538A1 (en) * 1989-07-25 1991-01-31 Goedecke Ag INDOLOCARBAZOL AND THEIR USE
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
WO1993007153A1 (en) * 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
EP0541486A1 (en) * 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclic conjugates
WO1993018771A1 (en) * 1992-03-24 1993-09-30 Asahi Kasei Kogyo Kabushiki Kaisha PLATELET AGGLUTINATION INHIBITOR CONTAINING STAUROSPORINE η-LACTAM DERIVATIVE
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69331228T4 (en) * 1992-09-21 2002-09-05 Kyowa Hakko Kogyo Co., Ltd. MEDICINE FOR THROMBOZYTOPENIA
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2154698C (en) 1993-01-28 2010-02-23 Lawrence Leroy Kunz Therapeutic inhibitor of vascular smooth muscle cells
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
WO1995002057A1 (en) * 1993-07-09 1995-01-19 The Institute Of Cancer Research Protein tyrosine kinase and ligands thereof
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
EP0711557A1 (en) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Base for formulating pharmaceutical agents
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
PT912184E (en) 1996-06-25 2002-12-31 Cephalon Inc USE OF A K-252A DERIVATIVE FOR THE TREATMENT OF CENTRAL OR PERIPHERAL NERVOUS SIETMA DISEASES AND CITOQUINE OVER-PRODUCTION
ES2388248T3 (en) 1997-03-31 2012-10-11 Boston Scientific Scimed Limited Dosage form comprising taxol in crystalline form
BR9915569A (en) * 1998-11-23 2001-08-14 Novartis Ag Method for the treatment of ocular neovascular diseases
PL409579A1 (en) 2001-02-19 2015-03-02 Novartis Ag Treatment of cancer
PT1392313E (en) 2001-05-16 2007-07-17 Novartis Ag Combination comprising n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido
ES2269793T3 (en) 2001-10-30 2007-04-01 Novartis Ag DERIVATIVES OF STAUROSPINE AS INHIBITORS OF THE ACTIVITY OF THYROSINE QUINASA RECEPTORA FLT3.
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0410439A (en) 2003-05-19 2006-06-06 Irm Llc immunosuppressive compounds and compositions
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
BRPI0413439A (en) 2003-08-08 2006-10-17 Novartis Ag combinations comprising staurosporines
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007002415A (en) * 2004-08-31 2007-04-23 Novartis Ag Combined use of prame inhibitors and hdac inhibitors.
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
RU2487711C2 (en) 2005-11-21 2013-07-20 Новартис Аг Treating neuroendocrine tumours
PT2676953T (en) 2008-12-18 2017-06-29 Novartis Ag Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3 -trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid for use in the treatment of lymphocyte mediated diseases
CA2747558A1 (en) 2008-12-18 2010-07-15 Novartis Ag New salts
CN102256942B (en) 2008-12-18 2013-07-24 诺瓦提斯公司 New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzyl) -azetidine-3-formic acid
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
IT202000004291A1 (en) * 2020-03-02 2021-09-02 Indena Spa PROCESS FOR THE PURIFICATION OF CARBAZOLIC INDOLE ALKALOIDS
CN112812129A (en) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 Novel crystalline form of midostaurin, process for its preparation and its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007105A1 (en) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives

Also Published As

Publication number Publication date
ES2083956T3 (en) 1996-05-01
ATE134375T1 (en) 1996-03-15
IL86632A0 (en) 1988-11-30
FI89362C (en) 1993-09-27
GR3019064T3 (en) 1996-05-31
YU115488A (en) 1989-12-31
IE70523B1 (en) 1996-12-11
FI882808A7 (en) 1988-12-16
AU617324B2 (en) 1991-11-28
JPS6434989A (en) 1989-02-06
NO170634C (en) 1992-11-11
EP0296110B1 (en) 1996-02-21
FI882808A0 (en) 1988-06-13
CA1337763C (en) 1995-12-19
JP2708047B2 (en) 1998-02-04
NO882613D0 (en) 1988-06-14
DK324888D0 (en) 1988-06-14
EP0296110A2 (en) 1988-12-21
KR890000494A (en) 1989-03-15
NO882613L (en) 1988-12-16
PT87719B (en) 1992-10-30
NO170634B (en) 1992-08-03
KR970001529B1 (en) 1997-02-11
HK1003788A1 (en) 1998-11-06
PT87719A (en) 1988-07-01
NZ225018A (en) 1990-09-26
DK324888A (en) 1988-12-16
IE881787L (en) 1988-12-15
EP0296110A3 (en) 1991-02-27
DK175507B1 (en) 2004-11-15
DE3855015D1 (en) 1996-03-28
HU201329B (en) 1990-10-28
AU1757188A (en) 1988-12-15
HUT47587A (en) 1989-03-28
FI89362B (en) 1993-06-15

Similar Documents

Publication Publication Date Title
MY104316A (en) Deravatives substituted at methylamino nitrogen
DK0379979T3 (en)
DK0582788T3 (en) 7- (Substituted) -9 - [(substituted glycyl) -amido] demethyl-6-deoxytetracyclines
YU43702B (en) Process for obtaining new 1,8-naphtirydinic derivatives
PT82854A (en) Process for the preparation of pyridonocarboxylic acid derivatives
MY130736A (en) Imidazo(4,5-c) pyridin-4-one derivatives
FR2495612B1 (en)
GR3003738T3 (en)
GR3021529T3 (en) Pyrrolidine derivatives
ZA862348B (en) Diamine derivatives
TW257758B (en) Piperazine derivatives (1)